Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Jun 21, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	3,768	$536.37	57,718
Jun 21, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	4,154	$535.63	61,486
Jun 21, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	8,236	$534.48	65,640
Jun 21, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	7,494	$533.66	73,876
Jun 21, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	738	$532.89	81,370
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	7	$486.31	517,799
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	1,693	$485.63	517,806
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	345	$484.72	519,499
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	355	$483.80	519,844
Dec 30, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	130,714	$483.25	750,224

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media